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What this study adds?
Turkish people has a similar RET proto-oncogene mutation 
distribution when compared to other Mediterranean countries i.e. 
Italy and France. Despite complimentary RET gene testing by the 
courtesy of Society of Endocrinology and Metabolism of Turkey, 
the number of the PTx in Turkey is limited and relatively late in 
the lifespan of the gene carriers. This is mainly due to patient and 
family incompliance and incomplete family counselling.
What is already knoWn on this topic?
Genetic screening of germline RET mutations provides the early 
diagnosis of hereditary cases. Prophylactic thyroidectomy (PTx) is 
the only preventive option for mutation carrier family members.
Objective: This retrospective multicenter study, centrally conducted and supported 
by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the 
impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) 
patients. Surgical timing, adequacy of the treatment, and frequency of prophylactic 
thyroidectomy (PTx) in mutation carriers were also assessed.
Methods: Genetic testing for MTC and pheochromocytoma was conducted between 
July 2008 and January 2012 in 512 patients. Application forms and RET mutation 
analyses of these patients whose blood samples were sent from various centers 
around Turkey were assessed retrospectively. An evaluation form was sent to the 
physicians of the eligible 319 patients who had confirmed sporadic MTC, familial 
MTC (FMTC), multiple endocrine neoplasia type 2 (MEN2), or who were mutation 
carriers. Physicians were asked to give information about the surgical history, latest 
calcitonin levels, morbidity, mortality, genetic screening, and PTx among family 
members. Twenty-five centers responded by filling in the forms of 192 patients.
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Introduction
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine 
tumor of the thyroid gland and accounts for 5% of thyroid 
cancers. The tumor originates from parafollicular ‘C’ cells 
and secretes calcitonin (CT). MTC mainly occurs sporadically 
(70-75%) (1). Hereditary syndromes of germline RET proto-
oncogene mutations are the cause of MTC in the remaining 
25-30% of patients. 
The RET proto-oncogene is located on chromosome 10 
(10.q11.2). It is a member of the receptor tyrosine-kinase 
family and comprises 21 exons. ‘C’ cells of the thyroid gland, 
parathyroid glands, adrenal medulla, urogenital system all 
express RET proto-oncogene (2). Various germline mutations 
of RET proto-oncogene cause distinct clinical features and 
influence the course of the disease (3). Multiple endocrine 
neoplasia type 2 (MEN 2) and familial MTC (FMTC) are both 
autosomal dominant inherited hereditary cancer syndromes. 
MEN2A accounts for 80% of hereditary MTC syndromes; 
consists of MTC in all patients, pheochromocytoma in 50% 
and primary hyperparathyroidism in 20-30% of patients (4). 
Cutaneous lichen amyloidosis (10%) and Hirschprung disease 
(7%) may also develop in MEN2A patients (5,6). MEN2A 
prevalence is estimated to be 1 per 50.000 and age of diagnosis 
is usually 20-30 years. De novo mutations may be responsible 
in up to 5% of MEN2A patients (7). Codon 634 mutations are 
the most frequent mutations in many of European countries 
(8,9). 
MEN2B is characterized with MTC, pheochromocytoma, 
mucosal neuromas, ganglioneuromatosis of the gut, and 
marfanoid habitus. This syndrome is caused by autosomal 
dominant genetic inheritance and de novo mutations equally 
(10). Prognosis of MEN2B is worse than MEN2A since MTC is 
more aggressive (11). 
FMTC is classically characterized by only hereditary 
predisposition to MTC for at least three generations (12). 
Germline mutations of the RET proto-oncogene are found 
in 98% of MEN2A, 95% of MEN2B, and in 88% of FMTC 
patients (13). Germline RET mutations can also be found in 
7-10% of apparently sporadic forms of MTC by routine RET 
screening (14,15). Hence, only genetic testing could rule out 
hereditary forms of MTC. 
Genetic screening of germline RET mutations is also 
the means for the early diagnosis of hereditary cases. 
Prophylactic thyroidectomy (PTx) is the only preventive option 
for mutation carrier family members. The association between 
RET mutations (genotype) and the biological behavior of 
tumor (phenotype) is well documented (3). Current guidelines 
recommend to consider risk stratification, mainly depending on 
the type of the mutation, in decisions on the timing of PTx (16). 
Age, family history, and basal/stimulated serum CT levels are 
the other factors which may have impact on the timing of PTx. 
In 2009, American Thyroid Association (ATA) recommended 
a 4-level risk classification for RET mutation carriers. PTx was 
recommended in the first year of life for MEN2B (M918T, 
A883F), before 5 years of age for subjects with level C (634 
mutations) and also for level B (609, 611, 618, 620, 630, 631 
mutations). The lower risk category (level A) involves distal 
codons (768, 790, 791, 804, 891). Family history of tumor 
behavior and family preference for these rare mutations 
with low genetic penetrance also need to be considered in 
decisions for surgery. However, there is no consensus on the 
management of these subjects (6,16,17,18).
This retrospective multicenter study aimed to evaluate the 
impact of free RET proto-oncogene testing of MTC patients. All 
data were evaluated in one center. The study was supported 
by the Society of Endocrinology and Metabolism of Turkey 
(SEMT). Adequacy of early diagnosis, surgical timing, and 
frequency of PTx in mutation carriers were also assessed.
Methods
Genetic testing for MTC and pheochromocytoma was 
conducted between July 2008 and January 2012 in 512 
patients. Application forms and RET mutation analyses of these 
512 patients whose blood samples were sent from various 
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Results: Among the 319 patients, RET mutation was detected in 71 (22.3%). Cys634Arg mutation was the most prevalent mutation (43.7%), followed by Val804Met in 18 patients 
(25.4%), and Cys634Tyr in 6 patients (8.5%). Among 192 MTC patients, the diagnosis was sporadic MTC in 146 (76.4%), FMTC in 14 (7.3%), MEN2A in 15 patients (7.9%), and 
MEN2B in one patient. The number of mutation carriers among 154 apparently sporadic MTC patients was 8 (5.2%). Ten patients were submitted to PTx out of twenty-four 
mutation carriers at a mean age of 35±19 years. 
Conclusion: Turkish people have a similar RET proto-oncogene mutation distribution when compared to other Mediterranean countries. Despite free RET gene testing, the 
number of the PTx in Turkey is limited and relatively late in the life span of the carriers. This is mainly due to patient and family incompliance and incomplete family counselling. 
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centers around Turkey were assessed retrospectively. Patients 
with pheochromocytoma without detected mutations and RET 
negative relatives of hereditary MTC patients were excluded. 
A total of 319 patients with familial/sporadic MTC, MEN2, 
and mutation carriers from known MEN2/FMTC families were 
found to be eligible for retrospective analysis. An evaluation 
form including information on the surgical history, latest CT 
levels, survival of the patients, and PTx had been prepared 
and sent to several physicians working in centers around the 
country. Twenty-five centers responded by filling in the forms 
of 192 patients. 
Patients who were considered to be sporadic cases by 
their physicians before mutation analysis were categorized as 
‘apparently sporadic’ cases. After the final analysis of the RET 
mutations and of the evaluation forms, the final diagnoses were 
categorized as MEN2A, familial/sporadic MTC, and mutation 
carriers from MEN2A/FMTC families. 
The study was approved by the Local Ethics Committee 
of Ankara University Faculty of Medicine (September 5, 2012).
RET Mutation Analysis 
RET mutation analyses were performed in Düzen Laboratory 
Groups. Genomic DNA from patients was isolated from 
peripheral blood leukocytes automatically by MagNA Pure LC 2.0 
(Roche Applied Science). RET gene exons 1-20 were amplified 
by polymerase chain reaction (PCR) using previously reported 
primers flanking the intron-exon junctions. PCR amplification of 
the exons 1-20 was carried out in a 25 µl PCR mix containing 
5 ng genomic DNA, 0.1 µM of each primer, 200 µM of each 
dNTP, 1.5 mM MgCl, and 1.25 U Taq polymerase (19,20). PCR 
[touchdown (TD) TD-PCR] was carried out. TD-PCR cycling 
program was: initial denaturation at 95 oC for 15 min followed 
by 10 cycles of 1 min at 95 oC, 1 min at 62 oC with an 0.5 oC 
decrease of temperature per cycle and 1 min at 72 oC and an 
additional 25 cycles of 1 min at 95 oC, 1 min at 57 oC, 1 min at 
72 oC and 10 min at 72 oC for final extension. The amplicons 
were analyzed in ethidium bromide-stained agarose gels and 
showed a single band with expected size. Then, amplicons 
were sequenced in an automated sequencer (ABI PRISM 
3130 Genetic Analyzer; Applied Biosystems, Foster City, CA) 
using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) according to the manufacturer’s instructions. The 
sequence data was analyzed by using SeqScape version 2.7 
(Applied Biosystems) and Sequencing Analysis version 5.1 
(Applied Biosystems) softwares. The results were interpreted 
by a professor in medical genetics. 
Statistical Analysis
Statistical analyses were performed using Statistical 
Package for the Social Sciences software, version 20.0 (IBM 
Corp, NY, and USA). Categorical data were compared using 
the chi-square Fisher exact test. Group data with a normal 
distribution were compared using the Student t-test or analysis 
of variance, and nonparametric data were compared using the 
Mann-Whitney U or Kruskal-Wallis tests. Values were expressed 
as mean ± standard deviation or median as appropriate. A 
p-value <0.05 was considered statistically significant.
Results
Figure 1, organized as a flow chart, depicts the numbers 
of patients included in the study at each step of the analysis. 
Between 2008 and 2012, among the 319 patients with 
hereditary/sporadic MTC whose blood samples were sent 
for RET analysis, mutation was detected in 71 patients 
(22.3%). Codon 634 mutation was detected in 39 (54.9%) 
patients. Cys634Arg was the most prevalent mutation (n=31) 
and accounted for 43.7% of all mutations. Cys634Tyr and 
Cys634Gly mutations were detected in 6 patients (8.5%) 
and in 2 patients (<1%), respectively. Val804Met germline 
mutation accounted for 25.4% of mutations. Distribution of 
RET mutations is summarized in Table 1. 
Among the 192 MTC patients with available clinical 
information, 146 patients had sporadic MTC, 15 patients 
MEN2A, 14 patients FMTC, and one subject had MEN2B. 
Sixteen patients were mutation carriers from known families. 
However, so-called FMTC patients may not fulfill the diagnostic 
criteria yet since three generations of follow-up is mandatory 
(12). 
Distribution of RET proto-oncogene mutation in 191 patients 
with available clinical information is summarized in Table 2, and 
distribution of RET mutations according to final diagnosis is 
summarized in Table 3. One MEN2B patient with Met918Thr 
mutation was excluded before statistical analyses.
RET mutation was detected in 8 of 154 patients (5.2%) 
defined as ‘apparently sporadic’ cases. Among these patients, 
three had Cys634Arg, three Val804Met, one Cys618Ser, and 
one subject had Y790Phe mutation. 
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Figure 1. The distrubition of diagnosis for 191 medullary thyroid 
carcinoma patients with available clinical information (multiple 
endocrine neoplasia type 2 B patient was excluded). MTC: Medullary 
thyroid carcinoma, MEN2A: multiple endocrine neoplasia type 2 A
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Mean age at diagnosis was similar in the two genders 
(44.2±14 years in females vs. 44.6±13.6 years in males, p=0.7), 
but was significantly lower in the patients diagnosed with 
genetic testing compared to those diagnosed with classical 
clinical features (31±18.2 years vs. 46.5±12.7 years, p<0.01). 
Mean age at diagnosis was also not statistically different 
between sporadic MTCs (47.6±1.05 years) and FMTCs 
(41.3±2.9 years) (p>0.05). MEN2A patients were younger 
(35.6±2.78 years) than sporadic and FMTCs at presentation 
(p<0.01) (a summary of preoperative clinical data is given in 
Table 4).
Mean follow-up period was 40±27 months in the whole 
group. The stage of tumor at diagnosis and preoperative CT 
levels are summarized in Table 4. Preoperative CT level was 
significantly higher in sporadic cases compared with the 
MEN2A and FMTCs (p<0.05) (Table 4). 
Follow-up data was available for 138 patients. On their most 
recent follow-up visit, 80 patients (58%) were in full remission, 
21 patients (15%) had locoregional disease (17 operable, 4 
inoperable) and 29 (21%) had distant metastases. Seven 
sporadic and one MEN2A patient (6%) died due to distant 
metastases. 
Sorafenib was the most preferred chemotherapeutic drug 
in metastatic patients (n=14). Conventional chemotherapeutics 
were chosen for 9 metastatic patients.
The mean number of surgical procedures was not statistically 
different between sporadic (1.67±1.05) and hereditary cases 
(1.31±1.5) (p=0.09). 
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Table 1. Distribution of RET proto-oncogene mutations in 71 out of 
319 patients with hereditary sporadic medullary thyroid carcinoma 
or pheochromocytoma who had been tested for RET proto-oncogene
N % Frequency of 
mutations % (n=71)
Cys634arg 31 9.7 43.7
Val804Met 18 5.6 25.4
Cys634Tyr 6 1.8 8.5
Tyr791Phe 4 1.2 5.6
Cys618Ser 3 <1 4.2
Met918Thr 2 <1 2.8
Cys634Gly 2 <1 2.8
Y790Phe 1 <1 1.4
Tyr790Phe 1 <1 1.4
Leu790Phe 1 <1 1.4
Ser891Ala 1 <1 1.4
D631Y 1 <1 1.4
Total 71 22.3 100.0
Table 2. Distribution of results of the RET proto-oncogene testing in 
191 patients with available clinical information
N % Frequency in mutations 
% (n=45)
No mutation 146 76.4 -
Cys634Arg 15 8.0  33.5
Cys634Tyr 7 3.6  16.0
Val804Met 15 8.0  33.5
Cys618Ser 2 1.0  4.0
Y790Phe 3 1.5  7.0
Tyr791Phe 2 1.0  4.0
D631Y 1 0.5  2.0
Total 191 100.0 100.0
Table 3. Distribution of RET mutations according to final diagnosis
Diagnosis Cys634Arg Cys634Tyr Val804Met Cys618Ser Tyr791Phe Y790Phe D631Y
MEN2A 9 2 1 2 1 - -
FMTC 2 - 11 - - 1 -
Mutation carrier 4 5 3 - 1 2 1
MEN2A: multiple endocrine neoplasia 2 A, FMTC: familial medullary thyroid cancer
Table 4. Preoperative clinical data of patients* 
Sporadic 
MTC
MEN2A FMTC p
Age (Mean, years) 47.6±1.05 35.6±2.78 41.3±2.9 p<0.01
Stage at diagnosis
 Stage I
 Stage II
 Stage III
 Stage IV
41
7
17
26
6
2
4
1
8
0
3
2
NS
NS
NS
p<0.01
CT (mean, pg/mL) 1072±1102 704±594 254±569 p<0.05
MTC: Medullary thyroid carcinoma, CT: calcitonin, FMTC: familial medullary thyroid 
carcinoma, MEN2A: multiple endocrine neoplasia type 2 A, NS: non significant
*Tumor stage at the time of diagnosis was available for 117 patients
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A significant number of mutation carriers (n=14) had not 
been operated yet although RET mutation carrier status was 
known at least for a year. Three out of fourteen subjects had 
elevated basal CT levels at the time of the study (Table 5). PTx 
or total thyroidectomy with central lymph node dissection was 
performed only in 10 out of 24 patients (41.6%). Mean age at 
thyroidectomy was 35±19 (12-60) years. Our study population 
included only five pediatric cases, and three of them had not 
undergone PTx although they had Codon 634 mutation.
Discussion
This retrospective multicenter study aimed to evaluate the 
impact of complimentary RET proto-oncogene testing in MTC 
patients. The timing of the surgical intervention, adequacy of 
diagnosis, treatment in familial/sporadic MTCs, and frequency 
of PTx for mutation carriers were also assessed. 
More than 145 germline mutations of RET proto-oncogene 
have been identified during the past 20 years, and it has been 
shown that common mutations are localized in eight exons 
(exons 5, 8, 10, 11, 13, 14, 15, 16) (21). Previously, the approach 
for the screening of family members of this autosomal dominant 
inherited disorder consisted of repeated analyses of basal and/
or stimulated CT measurements. In 1993, two different groups 
identified RET proto-oncogene mutations as the cause of 
hereditary cases and MEN2 syndromes, and RET genetic 
testing has since become the method of screening gradually 
(22,23). The prognosis of MTC is not favorable compared to 
differentiated thyroid carcinomas. Tumor stage at the time of 
diagnosis is the most important prognostic factor (24). Curability 
of metastatic disease is quite difficult. When possible, early 
diagnosis and treatment is the cornerstone of the management.
In asymptomatic carriers, mutation analysis facilitates early 
diagnosis and treatment of the disease. The ATA guidelines 
recommend the use of a four-level risk classification for RET 
mutations (16). Risk categories are important to decide the 
timing of PTx for mutation carriers. Although the biological 
behavior of the disease is usually comparable within the families, 
it can occasionally be variable within the same family (25,26). 
It is well-known that early PTx reduces cancer mortality 
to lower than 5% in MEN2A patients (27). The primary 
goal of early prophylactic surgery is to prevent lymph node 
metastases. Unfortunately, cervical lymph node metastases 
are found in 70% of patients when the nodule becomes 
palpable (28). On the other hand, surgery at early ages is 
associated with increased morbidity (29). Thus, annual follow-
up of stimulated CT has been suggested to guide the timing 
and extent of surgery. Elisei et al (30) achieved cure in RET 
mutation carriers who were treated early after stimulated CT 
levels were detected to be elevated. However, in a recent 
study, it has been reported that basal and stimulated CT levels 
failed to detect MTC before surgery in three of the 31 (10%) 
mutation carriers (31). European Multiple Endocrine Neoplasia 
(EUROMEN) study also demonstrated that 75% (12/16) of 
codon 634 mutations developed MTC before the age of five. 
Thus, early diagnosis with RET proto-oncogene testing, risk 
stratification, and stimulated CT levels are the mainstay for the 
timing of PTx in hereditary cases. 
Our results in this retrospective analysis showed that, 
although free genetic testing is available with the courtesy 
of SEMT and conducted centrally by the society itself, the 
number of PTx is still low in Turkey and the timing of surgical 
intervention is late. Current data showed that prophylactic/total 
thyroidectomy was performed only in 10 patients out of 24 
mutation carriers identified and mean age of hereditary cases 
at surgery was relatively late [35±19 years (12-60)]. Fourteen of 
the known mutation carriers had not yet undergone surgery at 
the time of the study due to patient and family incompliance 
and/or incomplete family counselling. Unfortunately, people 
deny genetic diseases, parents still have hesitations about 
surgical interventions for their children, especially during 
younger ages, and healthcare professionals may not be able to 
overcome these problems. 
MEN2A is frequently caused by the mutations in codons 
634, 620, 618, 611, 609. Mutations at codon 634 of exon 11 
account for 85% of cases and approximately half of them are 
cysteine to arginine amino acid substitution (Cys634Arg) (32). 
In FMTC, more than 85% of patients have mutations in exons 
10 and 11 (22). Other rare mutations were described in exon 
13 (codons 768, 790, 791), exon 14 (codons 804,844) and exon 
15 (codon 891). 
This is the largest mutation analysis ever performed in 
Turkish population and most common RET proto-oncogene 
Aydoğan Bİ et al. 
Distribution of RET Mutations and Treatment Approaches in Medullary Thyroid Carcinoma in Turkey
Table 5. Mutations and age of the patients with known RET mutation who had not yet undergone thyroid surgery
Patient Age (years) RET mutation Patient Age (years) RET mutation
1-H.K. 29 Val804Met 8-A.K. 7 Cys634Tyr
2-A.K. 27 Val804Met 9-K.K. 57 Cys634Tyr
3-B.A. 17 Tyr791Phe 10-E.P. 4 Cys634Arg
4-M.B. 34 Val804Met 11-İ.B. 47 Tyr791Phe
5-Ü.Y. 33 Tyr791Phe 12-M.K. 53 Cys634Tyr
6-S.E. 23 Cys634Arg 13-N.K. 56 Cys634Tyr
7-H.E. 46 Cys634Arg 14-D.Ö. 5 Cys634Arg
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mutation reported was codon 634 mutation (54.9%). Val804 
mutation was also an important mutation, accounting for 25.4% 
of RET mutations in Turkish population, especially in FMTC 
patients (79%) although some of these patients did not fulfill 
the diagnostic criteria yet. Codon 804 mutation is considered 
to be a low risk in ATA 2009 guidelines, and individual-, patient-, 
and family-based management is suggested. In our series, 
11 patients with FMTC had Val804Met mutation and they 
underwent surgery at a mean age of 47.2±10.9. Two patients 
had local recurrence, one had metastatic disease, and despite 
relatively late age of surgery, the remaining eight subjects were 
in remission. Surgical technique could of course be questioned 
in the local recurrence. Thus, our results are concordant with ATA 
guidelines, where distal codons (768, 790, 791, 804, 891) were 
categorized as lower risk mutations with low genetic penetrance.
EUROMEN multicenter study showed that the most 
prevalent RET mutation in the European population 
was Cys634 with 67.6% frequency (6). The multicenter 
ItaMEN network analysis demonstrated that codon 634 at 
exon 11 was the most affected codon (34.8%) followed 
by Val804Met mutation (19.6%) among Italian MEN2 
syndromes (33). Val804 mutations were threefold frequent 
in Italian and French when compared to German families. 
These data are concordant with the results in our series 
since Val804Met mutations are also prevalent in Turkey 
(25.4%). Sánchez et al (34) reported that the most frequent 
RET mutation in MEN2A Spanish families was C634Y, 
occurring in 73% (22/30) of cases and this finding was 
attributed to founder effect. A recent German study also 
demonstrated that RET mutations were distributed fairly 
similarly among German, French, and Italian families. The 
mutations in codon 634 were the most prevalent (36%), 
and codon 790 mutations were also frequent in Germany 
compared to Italy and France (13% vs. 4% and 4%) (35). In 
our series, codon 790 mutations were very rare, accounting 
for 1.4% of all mutations. Other studies from China, India, 
and Korea also demonstrated that Codon 634 mutations 
accounted for 60-80 % of hereditary cases. Interestingly, 
Val 804 mutation was not reported in China (36) and Korea 
(37) and had a lower frequency in a small Indian study (38) 
compared to current and other European studies (7% vs. 
25.4%) (33,35). 
Another important finding in accordance with previous 
findings of our group and of the others is that genetic 
testing revealed eight mutation carriers (hereditary cases) 
(5.2%) among 154 clinically diagnosed as sporadic MTCs 
(13,14). This data underlines the necessity of genetic 
screening for all MTC patients (15,16). On the other hand, 
frequency of mutation carriers among apparently sporadic 
cases was lower than in the previous TURKMEN study 
(10.7%), presumably due to increased awareness and 
genetic testing among physicians in our country. Current 
guidelines recommend genetic testing for all MTC cases 
and if positive, clinical screening for pheochromocytoma 
and primary hyperparathyroidism (16,21). In the rare 
situation when the clinical criteria for hereditary syndromes 
are present but RET mutation analyses are negative, 
clinical screening of siblings is also recommended. As a 
cost-effective approach, ATA and ETA recommend to test 
MEN2-specific exons (i.e. exons 10,11) principally and if 
found negative, continue testing for exons 13, 14, and 15 
subsequently (16,21). 
The mean number of surgical procedures were higher in our 
sporadic cases compared to familial cases, but no statistically 
significant difference was observed. These findings may 
reflect delayed timing of diagnosis and small number of PTx for 
hereditary cases. 
This study shows that the Turkish people has a similar 
RET proto-oncogene mutation distribution when compared 
to other Mediterranean countries such as Italy and France. 
Despite complementary RET gene testing made possible by 
the courtesy of SEMT, the number of the PTx in Turkey is 
limited and the surgical intervention is performed at a relatively 
late stage in the lifespan of the gene carriers. This is mainly 
due to patient and family incompliance and incomplete family 
counselling. Healthcare professionals seem to be unsuccessful 
to overcome these problems for the moment. Physicians and 
health authorities should be aware of this situation. Legal 
measures could be considered for the families who refuse 
healthcare for their children.  
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